NEWS

Attacking XIAP through Bcl-2. Focusing on Bcl-2’s effect on apoptosis in relation to XIAP can create more effective therapies to fight off prostate cancer. Read how taking a multi-targeting approach can make apoptosis more reliable.

Gene therapy for prostate cancer. Prostate cancer affects one in six men and is the second leading cause of cancer death among men in the US. Gene therapy shows promise as a treatment strategy that can target both localized and metastatic prostate cancer. View this web focus to read more about the field of prostate cancer gene therapy.

Nature Publishing Group and AstraZeneca are pleased to congratulate the 2007 AstraZeneca Scholarship award recipients, Kim et al., for their winning paper entitled "Characterization of the androgen receptor in a benign prostate tissue-derived human prostate epithelial cell line: RC-165N/human telomerase reverse transcriptase." The award is bestowed on the most significant original research paper published in 2007.

Submit your paper to Nature Precedings while your manuscript is under consideration. This archive provides a rapid way to disseminate emerging results and new theories, solicit opinions, and record the provenance of ideas. Register to submit documents now.